Integra LifeSciences (IART) Q3 2025 earnings summary

Executive summary

• Q3 2025 revenue reached $402.1 million, up 5.6% reported and 5% organic year-over-year, but below guidance due to supply interruptions in the CSS business.

• Adjusted EPS was $0.54, up 32% year-over-year and above guidance, reflecting strong cost control and operational efficiency; GAAP net loss was $5.4 million, improved from prior year.

• PriMatrix and Durepair were relaunched nearly a year ahead of schedule via dual sourcing; Braintree facility on track to resume production in June 2026, supporting SurgiMend relaunch in Q4 2026.

• Margin expansion program targets $25–$30 million in cost reductions in 2026 through productivity and efficiency initiatives.

• Progress continues on the Compliance Master Plan, operational excellence, and portfolio prioritization for long-term growth.

Financial highlights

• Q3 2025 revenue was $402.1 million, up 5.6% reported and 5% organic year-over-year; adjusted EPS was $0.54, up 31.7% year-over-year; adjusted EBITDA margin rose to 19.5%.

• GAAP gross margin was 51.5% (down from 52.6%); adjusted gross margin was 62.9% (down 10bps); operating cash flow was $40.9 million.

• GAAP net loss was $5.4 million; adjusted net income was $41.6 million.

• Free cash flow for Q3 was $25.8 million; adjusted free cash flow conversion was 61.9%.

• Operating expenses for Q3 2025 decreased 6.3% to $195.2 million, driven by lower R&D and SG&A costs.

Outlook and guidance

• Full-year 2025 revenue guidance revised to $1.62–$1.64 billion; adjusted EPS guidance to $2.19–$2.24.

• Q4 2025 revenue expected at $420–$440 million, with adjusted EPS of $0.79–$0.84; reported growth -5.1% to -0.6%, organic growth -5.9% to -1.4%.

• Gross margin for 2025 expected to decline by 260bps, mainly due to remediation and tariffs.

• Modest revenue growth anticipated in 2026, with continued focus on operational execution and cost management.

• Cash, cash equivalents, and short-term investments are considered sufficient to finance operations and capital expenditures for the next twelve months.